Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Mohit Oberoi

This Dividend Stock Yields Nearly 8% and Trades at Depressed Valuations: Time to Buy?

Pfizer (PFE) investors are bound to be disappointed with the stock’s price action. 

With a year-to-date loss of 16.7% as of April 15, the stock is underperforming the S&P 500 Index ($SPX) by a good margin. The global pharmaceutical giant’s underperformance is not limited to 2025. The stock lost 41% in 2023 and 2% in 2024, even as the broader markets delivered double-digit returns in both years.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.